Cubist Pharmaceuticals and Optimer Pharmaceuticals seal merger and acquisition activity under which Cubist will acquire all of the outstanding shares of Optimer common stock for $10.75 per share in cash, or approximately $535 million on a fully diluted basis.
In addition to the upfront cash payment, each stockholder of Optimer will receive a Contingent Value Right , which is expected to be publicly traded, entitling the holder to receive an additional one-time cash payment of up to $5.00 for each share they own if certain net sales of DIFICID(fidaxomicin) are achieved, or a total transaction value of up to $801 million on a fully diluted basis.
For further deal information visit Current Agreements (subscription required)
Read: more on Cubist company profile, recent partnering, M&A and financing news and articles
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Merger and Acquisition Terms and Agreements
Report: Partnering Agreements with Cubist 2005-2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View:Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity